Suchergebnisse - "Arnan, Montserrat"

PubPharm (76)

1

Germline assessment for alloHSCT candidates over 50 years : A 'Fast-Track' screening in myeloid neoplasms

enthalten in: British journal of haematology | 2024

von Torres-Esquius, S. | Beas, F. | Chen-Liang, T. | +18

2

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

enthalten in: British journal of haematology | 2024

von Castaño-Díez, S. | Pomares, H. | Esteban, D. | +17

3

Biological basis of extensive pleiotropy between blood traits and cancer risk

enthalten in: Genome medicine | 2024

von Pardo-Cea, M. | Farré, X. | Esteve, A. | +29

4

Biological basis of extensive pleiotropy between blood traits and cancer risk

enthalten in: Genome medicine | 2024

von Pardo-Cea, M. | Farré, X. | Esteve, A. | +29

5

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1) : a randomised, double-blind, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Haematology | 2024

von Zeidan, A. | Ando, K. | Rauzy, O. | +17

ErratumIn: Lancet Haematol. 2024 Feb 5;:. - PMID 38330978

6

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy

enthalten in: Cell reports. Medicine | 2023

von Hurtado-Navarro, L. | Cuenca-Zamora, E. | Zamora, L. | +23

7

Venetoclax with hypomethylating agents might lead to eradication of measurable residual disease (MRD) persisting after intensive chemotherapy in acute myeloid leukemia (AML) patients with mutated NPM1 and rearranged CBF

enthalten in: Leukemia research | 2023

von Jiménez-Vicente, C. | Martínez-Roca, A. | Pomares, H. | +15

8

Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE) : part one of a randomised, phase 2, dose optimisation study

enthalten in: The Lancet. Haematology | 2023

von Pabst, T. | Papayannidis, C. | Demirkan, F. | +23

CommentIn: Lancet Haematol. 2023 Nov;10(11):e868-e870. - PMID 37914475

9

Mutational Profile Enables the Identification of a High-Risk Subgroup in Myelodysplastic Syndromes with Isolated Trisomy 8

enthalten in: Cancers | 2023

von Toribio-Castelló, S. | Castaño, S. | Villaverde-Ramiro, �. | +8

10

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

enthalten in: Blood advances | 2023

von de Botton, S. | Fenaux, P. | Yee, K. | +26

1
2
3
4
5
6
7
8
Nächster »
[8]